1.
|
Phase: Phase III, Phase II Type: Treatment Status: Active Age: 19 to 70 Sponsor: Other Protocol IDs: F080429003, UAB-0775, NCT00714259
|
|
2.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: Hx-CD20-405, GENMAB-Hx-CD20-405, OHSU-2634, NCT00394836
|
|
3.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 110918, NCT01077518
|
|
4.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Supportive care, Treatment Status: Active Age: not specified Sponsor: NCI, Other Protocol IDs: 2448.00, NCI-2010-02035, P01CA018029, NCT01231412
|
|
5.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: BO21223, NCT01332968
|
|
6.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: RV-FOL-GELARC-0683C, 2011-002792-42, NCT01476787
|
|
7.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 to 75 Sponsor: Pharmaceutical / Industry Protocol IDs: SPI-ZEV-12-302, NCT01662102
|
|
8.
|
Phase: Phase III Type: Treatment Status: Active Age: 65 and over Sponsor: Pharmaceutical / Industry Protocol IDs: PCYC-1115-CA, 2012-003967-23, NCT01722487
|
|
9.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: Not specified Sponsor: NCI, Other Protocol IDs: 95-024, P30CA008748, MSKCC-95024, NCI-V95-0685, NCT00002663
|
|
10.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 70 and under Sponsor: Other Protocol IDs: BCM-H-19386, BCM-FAB, H 19386, NCT00625144
|
|
11.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: IRB# 29960007, NCT00634179
|
|
12.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: PSOC 2401, NCI-2010-00324, IR-6956, MERCK-PSOC-2401, NCT00918723
|
|
13.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: NU 05H9, STU00004871, NU-0522-060, MILLENNIUM-NU-05H9, NCT00372905
|
|
14.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 16 and over Sponsor: Other Protocol IDs: 2009-0546, NCT01096992
|
|
15.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 1001010838, NCT01147393
|
|
16.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: PSOC 2502, NCI-2010-00907, NCT01165112
|
|
17.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 101-10, NCT01306643
|
|
18.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 2011-001, NCT01416428
|
|
19.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 to 55 Sponsor: Pharmaceutical / Industry Protocol IDs: CHSC835X2201, NCT01474681
|
|
20.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: UPCC 11411, NCT01575860
|
|
21.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: 2011-203, NCT01609816
|
|
22.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: 2011-204, NCT01643603
|
|
23.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 to 65 Sponsor: Pharmaceutical / Industry Protocol IDs: BP-HM-001, NCT01744223
|
|
24.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 to 65 Sponsor: Other Protocol IDs: 201303012, NCT01747499
|
|
25.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 65 and over Sponsor: Other Protocol IDs: 2012-0086, NCT01752426
|